{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:33:59Z","timestamp":1786739639273,"version":"build-2736575974"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>\n                    We conducted a systematic review of analytical epidemiological studies to assess the association between ChAdOx1-S vaccination and thromboembolic, thrombocytopenic, and hemorrhagic events. We searched Medline, Embase, Google Scholar, WHO-COVID-19 database, and medRxiv for studies evaluating the association between ChAdOx1-S and vascular events. Primary outcomes of interest were cerebral venous sinus thrombosis, peripheral venous thrombosis (PVT), and thrombocytopenia. Two independent reviewers screened for eligible studies, extracted data, and assessed the risk of bias. The DerSimonian-Laird random effects model was used to pool the incidence rate ratios (IRRs) separately for the first and second doses. Heterogeneity was assessed using I\n                    <jats:sup>2<\/jats:sup>\n                    statistics. Twenty studies were included, of which 11 were self-controlled case series, and nine were cohort studies (254 million participants). Pooling of 17 studies showed a higher risk of cerebrovascular thrombosis (IRR = 3.5, 95% CI = 2.2\u20135.4, I\n                    <jats:sup>2<\/jats:sup>\n                    = 79%), PVT (IRR = 2.0, 95% CI = 1.1\u20133.5, I\n                    <jats:sup>2<\/jats:sup>\n                    = 95%) and thrombocytopenia (IRR = 1.6, 95% CI = 1.4\u20131.9, I\n                    <jats:sup>2<\/jats:sup>\n                    = 93%) among those who received ChAdOx1-S vaccination as compared to controls. No increased risk was seen after the second dose or for secondary outcomes. There is moderate-to-high certainty of the evidence for the increased risk of cerebral venous sinus thrombosis, PVT, and thrombocytopenia following the first dose of the ChAdOx1-S vaccine.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Systematic Review Registration:<\/jats:bold>\n                    PROSPERO CRD42022372768.\n                  <\/jats:p>","DOI":"10.4103\/ijcm.ijcm_676_23","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:01:17Z","timestamp":1720656077000},"page":"571-578","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Association between COVID-19 Vaccination (ChAdOx1-S) and Thromboembolic, Thrombocytopenic, Hemorrhagic Events: A Systematic Review and Meta-analysis of Analytical Epidemiological Studies"],"prefix":"10.4103","volume":"49","author":[{"given":"Raman S.","family":"Vaman","sequence":"first","affiliation":[{"name":"Scholar, ICMR-School of Public Health, ICMR- National Institute of Epidemiology, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthusamy S.","family":"Kumar","sequence":"additional","affiliation":[{"name":"Scientist C, ICMR-School of Public Health, ICMR- National Institute of Epidemiology, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathiresan","family":"Jeyashree","sequence":"additional","affiliation":[{"name":"Scientist E, ICMR-School of Public Health, ICMR- National Institute of Epidemiology, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Periasami","sequence":"additional","affiliation":[{"name":"Scholar, ICMR-School of Public Health, ICMR- National Institute of Epidemiology, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwan S.","family":"Abdulkader","sequence":"additional","affiliation":[{"name":"Scientist D, ICMR-School of Public Health, ICMR- National Institute of Epidemiology, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Murhekar","sequence":"additional","affiliation":[{"name":"Scientist G, ICMR-School of Public Health, ICMR- National Institute of Epidemiology, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"R1-20250304","article-title":"Global COVID-19 Vaccination Strategy in a Changing World","year":"2022"},{"key":"R2-20250304","article-title":"WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data","year":"2022"},{"key":"R3-20250304","article-title":"Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 VaxzevriaTM, SII COVISHIELDTM)"},{"key":"R4-20250304","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"R5-20250304","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"R6-20250304","doi-asserted-by":"crossref","first-page":"n699","DOI":"10.1136\/bmj.n699","article-title":"Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots","volume":"372","author":"Wise","year":"2021","journal-title":"BMJ"},{"key":"R7-20250304","article-title":"AstraZeneca\u2019s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low platelets","year":"2021","journal-title":"European Medicines Agency"},{"key":"R8-20250304","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1016\/j.vaccine.2022.06.014","article-title":"Vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: Description of a series of 39 cases in Brazil","volume":"40","author":"Mouta Nunes de Oliveira","year":"2022","journal-title":"Vaccine"},{"key":"R9-20250304","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R10-20250304","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"R11-20250304","article-title":"Proposal of a quality assessment tool for the evaluation of the methodological quality of self-controlled case series and self-controlled risk interval study designs","author":"Wachira","year":"2022","journal-title":"SciELO Preprints"},{"key":"R12-20250304","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/oxfordjournals.aje.a112220","article-title":"Estimability and estimation in case-referent studies","volume":"103","author":"Miettinen","year":"1976","journal-title":"Am J Epidemiol"},{"key":"R13-20250304","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R14-20250304","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1016\/j.vaccine.2022.05.075","article-title":"Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study","volume":"40","author":"Ab Rahman","year":"2022","journal-title":"Vaccine"},{"key":"R15-20250304","doi-asserted-by":"crossref","first-page":"100260","DOI":"10.1016\/j.lanepe.2021.100260","article-title":"Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: A national cohort study in England","volume":"13","author":"Andrews","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"R16-20250304","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.7326\/M22-0988","article-title":"Risk for myocardial infarction, stroke, and pulmonary embolism following COVID-19 vaccines in adults younger than 75 years in France","volume":"175","author":"Botton","year":"2022","journal-title":"Ann Intern Med"},{"key":"R17-20250304","doi-asserted-by":"crossref","first-page":"7167","DOI":"10.1038\/s41467-022-34668-w","article-title":"Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United Kingdom","volume":"13","author":"Burn","year":"2022","journal-title":"Nat Commun"},{"key":"R18-20250304","doi-asserted-by":"crossref","first-page":"e2217375","DOI":"10.1001\/jamanetworkopen.2022.17375","article-title":"Analysis of thromboembolic and thrombocytopenic events after the AZD1222, BNT162b2, and MRNA-1273 COVID-19 vaccines in 3 Nordic countries","volume":"5","author":"Dag Berild","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R19-20250304","doi-asserted-by":"crossref","first-page":"e12698","DOI":"10.1002\/rth2.12698","article-title":"Risk of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination prior to the recognition of vaccine-induced thrombocytopenia and thrombosis: A self-controlled case series study in England","volume":"6","author":"Higgins","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"R20-20250304","doi-asserted-by":"crossref","first-page":"n1931","DOI":"10.1136\/bmj.n1931","article-title":"Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: Self-controlled case series study","volume":"374","author":"Hippisley-Cox","year":"2021","journal-title":"BMJ"},{"key":"R21-20250304","doi-asserted-by":"crossref","first-page":"541","DOI":"10.7326\/M21-2452","article-title":"Association of AZD1222 and BNT162b2 COVID-19 vaccination with thromboembolic and thrombocytopenic events in frontline personnel: A retrospective cohort study","volume":"175","author":"Hviid","year":"2022","journal-title":"Ann Intern Med"},{"key":"R22-20250304","doi-asserted-by":"crossref","first-page":"e1003927","DOI":"10.1371\/journal.pmed.1003927","article-title":"First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales","volume":"19","author":"Kerr","year":"2022","journal-title":"PLoS Med"},{"key":"R23-20250304","doi-asserted-by":"crossref","first-page":"e071594","DOI":"10.1136\/bmj-2022-071594","article-title":"Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: International network cohort study from five European countries and the US","volume":"379","author":"Li","year":"2022","journal-title":"BMJ"},{"key":"R24-20250304","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1186\/s12879-021-06960-5","article-title":"Association of cerebral venous thrombosis with recent COVID-19 vaccination: Case-crossover study using ascertainment through neuroimaging in Scotland","volume":"21","author":"McKeigue","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R25-20250304","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","volume":"27","author":"Patone","year":"2021","journal-title":"Nat Med"},{"key":"R26-20250304","doi-asserted-by":"crossref","first-page":"n1114","DOI":"10.1136\/bmj.n1114","article-title":"Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: Population based cohort study","volume":"373","author":"Potteg\u00e5rd","year":"2021","journal-title":"BMJ"},{"key":"R27-20250304","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ana.26172","article-title":"COVID-19 vaccine-associated cerebral venous thrombosis in Germany","volume":"90","author":"Schulz","year":"2021","journal-title":"Ann Neurol"},{"key":"R28-20250304","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41591-021-01408-4","article-title":"First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland","volume":"27","author":"Simpson","year":"2021","journal-title":"Nat Med"},{"key":"R29-20250304","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1038\/s41467-022-32264-6","article-title":"Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland","volume":"13","author":"Simpson","year":"2022","journal-title":"Nat Commun"},{"key":"R30-20250304","article-title":"Cohort monitoring of 29 adverse events of special interest prior to and after COVID-19 vaccination in four large European electronic healthcare data sources","author":"Sturkenboom","year":"2022","journal-title":"MedRxiv"},{"key":"R31-20250304","doi-asserted-by":"crossref","first-page":"16406","DOI":"10.1038\/s41598-022-20118-6","article-title":"Risk of thrombocytopenic, haemorrhagic and thromboembolic disorders following COVID-19 vaccination and positive test: A self-controlled case series analysis in Wales","volume":"12","author":"Torabi","year":"2022","journal-title":"Sci Rep"},{"key":"R32-20250304","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejim.2022.03.002","article-title":"Thrombotic events following Covid-19 vaccines compared to Influenza vaccines","volume":"99","author":"Vallone","year":"2022","journal-title":"Eur J Intern Med"},{"key":"R33-20250304","doi-asserted-by":"crossref","first-page":"e1003926","DOI":"10.1371\/journal.pmed.1003926","article-title":"Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England","volume":"19","author":"Whiteley","year":"2022","journal-title":"PLoS Med"},{"key":"R34-20250304","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/S2214-109X(21)00545-3","article-title":"Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination","volume":"10","author":"Soboleva","year":"2022","journal-title":"Lancet Glob Health"},{"key":"R35-20250304","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12959-022-00370-6","article-title":"Vaccine-induced thrombotic thrombocytopenia (VITT): First report from India","volume":"20","author":"John","year":"2022","journal-title":"Thromb J"},{"key":"R36-20250304","doi-asserted-by":"crossref","first-page":"e069590","DOI":"10.1136\/bmj-2021-069590","article-title":"Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: Nationwide self-controlled cases series and matched cohort study","volume":"377","author":"Katsoularis","year":"2022","journal-title":"BMJ"},{"key":"R37-20250304","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/CIRCULATIONAHA.122.060785","article-title":"Association of COVID-19 with major arterial and venous thrombotic diseases: A population-wide cohort study of 48 million adults in England and Wales","volume":"146","author":"Knight","year":"2022","journal-title":"Circulation"},{"key":"R38-20250304","doi-asserted-by":"crossref","first-page":"2127572","DOI":"10.1080\/21645515.2022.2127572","article-title":"Comparative risk of cerebral venous sinus thrombosis (CVST) following COVID-19 vaccination or infection: A national cohort study using linked electronic health records","volume":"18","author":"Ohaeri","year":"2022","journal-title":"Hum Vaccines Immunother"},{"key":"R39-20250304","doi-asserted-by":"crossref","first-page":"7429","DOI":"10.1016\/j.vaccine.2021.10.079","article-title":"Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework","volume":"39","author":"Lau","year":"2021","journal-title":"Vaccine"},{"key":"R40-20250304","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14760584.2022.2020108","article-title":"Self-controlled case series design in vaccine safety: A systematic review","volume":"21","author":"Nie","year":"2022","journal-title":"Expert Rev Vaccines"}],"container-title":["Indian Journal of Community Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijcm.ijcm_676_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:30:48Z","timestamp":1786735848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijcm.ijcm_676_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijcm.ijcm_676_23","relation":{},"ISSN":["0970-0218","1998-3581"],"issn-type":[{"value":"0970-0218","type":"print"},{"value":"1998-3581","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2023-09-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}